What is the best way to use conjugate vaccines?

Current Opinion in Infectious Diseases

Volumn 24, Issue 3, 2011, Pages 219-224

  Seale, Anna ^a,b   Finn, Adam ^a,b,c  

^a UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UHB Education Centre   (United Kingdom)

Author keywords

colonization; conjugate vaccine; immunity

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; NEISSERIA MENINGITIDIS VACCINE; PNEUMOCOCCUS VACCINE; STREPTOCOCCUS VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; CONJUGATE; COST EFFECTIVENESS ANALYSIS; DIPHTHERIA; DRUG EFFECT; HERD IMMUNITY; HUMAN; INFLUENZA; MUCOSAL IMMUNITY; NEISSERIACEAE INFECTION; NONHUMAN; PERTUSSIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; TETANUS; TYPHOID FEVER;

HUMANS; IMMUNITY, HERD; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL VACCINES; SALMONELLA VACCINES; STREPTOCOCCAL VACCINES; VACCINATION; VACCINES, CONJUGATE;

EID: 79955522369     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283468996     Document Type: Article

References (54)

1. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction: eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008; 57:144-148.
2. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997; 337:970-976. (Pubitemid 27425953)
3. Trotter C, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-367. (Pubitemid 38970013)
4. Hviid A, Melbye M. Impact of routine vaccination with a conjugate Haemophilus influenzae type b vaccine. Vaccine 2004; 22 (3-4):378-382. (Pubitemid 37510268)
5. Käyhty H PH, Karanko V, MäkeläPH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147:1100.
6. Robbins J, Parke JC Jr, Schneerson R, Whisnant JK. Quantitative measurement of ?natural? and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res 1973; 7:103-110.
7. Paradiso P. Essential criteria for evaluation of pneumococcal conjugate vaccine candidates. Vaccine 2009; 27 (Suppl. 3):C15-C18.
8. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection: serum bactericidal antibody activity. Vaccine 2005; 23 (17-18):2222-2227. (Pubitemid 40341456)
9. Rose C, Romero-Steiner S, Burton RL, et al. Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera. Clin Vaccine Immunol 2011; 18:135-142.
10. Black S, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002; 21:810-815.
11. O?Brien K, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003; 362:355-361. (Pubitemid 36945058)
12. Klugman K, Madhi SA, Huebner RE, et al., Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341-1348. (Pubitemid 37186212)
13. Eskola J, Peltola H, Takala AK, et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med 1987; 317:717-722. (Pubitemid 17138201)
14. Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010; 17:840-847.
15. O?Brien K, Moïsi J, Romero-Steiner S, et al. Pneumococcal antibodies in a child with type 14 pneumococcal conjugate vaccine failure. Vaccine 2009; 13:1863-1868.
16. Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009; 374:1339-1350.
17. Eskola J, Ward J, Dagan R, et al. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999; 354:2063-2068.
18. Trotter C, McVernon J, Andrews NJ, et al. Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet 2003; 361:1523-1524. (Pubitemid 36566347)
19. Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010; 17:154-159.
20. Snape M, Kelly DF, Green B, et al. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J 2005; 24:128-131. (Pubitemid 40250770)
21. de Voer R, Mollema L, Schepp RM, et al. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine. PLoS One 2010; 5:e12144.
22. Blanchard-Rohner G, Galli G, Clutterbuck EA, Pollard AJ. Comparison of a limiting dilution assay and ELISpot for detection of memory B-cells before and after immunisation with a protein-polysaccharide conjugate vaccine in children. J Immunol Methods 2010; 358:46-55
23. McVernon J, Andrews N, Slack MPE, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 361:1521-1523. (Pubitemid 36566346)
24. Southern J, McVernon J, Gelb D, et al. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vaccine Immunol 2007; 14:1328-1333. (Pubitemid 350012976)
25. Adegbola R, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005; 366:144-150. (Pubitemid 40991215)
26. Slack M, Azzopardi HJ, Hargreaves RM, Ramsay ME. Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines. Pediatr Infect Dis J 1998; 17:S204-S207. (Pubitemid 28460574)
27. Jacups SP, Morris PS, Leach AJ. Haemophilus influenzae type b carriage in Indigenous children and children attending childcare centers in the Northern Territory, Australia, spanning pre and postvaccine eras. Vaccine 2010 [Epub ahead of print].
28. Howie S, Antonio M, Akisanya A, et al. Re-emergence of Haemophilus influenzae type b (Hib) disease in The Gambia following successful elimination with conjugate Hib vaccine. Vaccine 2007; 25:6305-6309. (Pubitemid 47088758)
29. Ramsay M, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357:195-196. (Pubitemid 32108093)
30. Ramsay M, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326:365-366. (Pubitemid 36241472)
31. Maiden M, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737-743. (Pubitemid 351364476)
32. Pollard A, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9:213-230.
33. Bidmos F, Neal KR, Oldfield NJ, et al. Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 University Student Cohort. J Clin Microbiol 2011; 49:506-512.
34. Burki T. The beginning of the end for the meningitis bel' Lancet Infect Dis 2011; 11:19-20.
35. Kristiansen P K, DiomandéF, Wei SC, et al. Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol 2011; 18:435-443.
36. Whitney C, Farley MM, Hadler J, et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 248:1737-1746. (Pubitemid 36514704)
37. Kaye P, Malkani R, Martin S, et al. Invasive pneumococcal disease (IPD) in England and Wales after 7-valent conjugate vaccine (PCV7); potential impact of 10 and 13-valent vaccines; 2009. http://www.hpa.org.uk/web/HPAweb- File/HPAweb-C/1245581527892 [Accessed 18 March 2011].
38. Goldblatt D, Southern J, Ashton L, et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 2006; 25:312-319.
39. Centers for Disease Control and Prevention C. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease: United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54: 893-897.
40. de Roux A, Schmöle-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46:1015-1023. (Pubitemid 351589866)
41. Watera C, Nakiyingi J, Miiro G, et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 2004; 18:1210-1213. (Pubitemid 38738524)
42. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812-822
43. Gessner B, Mueller JE, Yaro S. African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults. BMC Infect Dis 2010; 10:22
44. Weinberger DM, Harboe ZB, Sanders EA, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010; 51:692-699.
45. Ihssen F KM, Dilettoso S, Tanner C, et al. Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fac 2010; 9:61.
46. Lin F, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344:1263-1269. (Pubitemid 32372960)
47. Micoli F, Rondini S, Pisoni I, et al. Vi-CRM(197) as a new conjugate vaccine against Salmonella typhi. Vaccine 2010; 29:712-720.
48. International Clinical Trials Registry Platform. A phase I, randomized, singleblind, controlled, single center study to evaluate the safety and immunogenicity of a dose range of glycoconjugate antigen vaccine of Group B streptococcus in healthy women 18-40 years of age 2009. http://apps.who.int/ trialsearch/Trial.aspx?TrialID=NCT00645346 [Accessed 18 March 2011].
49. Hillier S. Progress made on a GBS vaccine. 47th Annual Meeting of the Infectious Diseases Society of America in Philadelphia. Philadelphia, United States; 2009. http://www.niaid.nih.gov/news/newsreleases/2009/Pages/ strepvax.aspx [Accessed 18 March 2011].
50. Abdullahi O, Nyiro J, Lewa P, et al. The descriptive epidemiology of Streptococcus pneumoniae and Haemophilus influenzae nasopharyngeal carriage in children and adults in Kilifi district, Kenya. Pediatr Infect Dis J 2008; 27:59-64.
51. Afsdottir T, Lingnau K, Nagy E, Jonsdottir I. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice. Scand J Immunol 2009; 69:194-202.
52. Zhu Y, Cai CS, Zhang W, et al. Immunoproteomic analysis of human serological antibody responses to vaccination with whole-cell pertussis vaccine (WCV). PLoS One 2010; 5:e13915.
53. Molzen T, Burghout P, Bootsma HJ, et al. Genome-wide identification of Streptococcus pneumoniae genes essential for bacterial replication during experimental meningitis. Infect Immun 2010; 79:288-297.
54. Moffitt K, Gierahn TM, Lu YJ, et al. T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 2011; 9:158-165.